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Abstract 
 
Background: The aim of this study was to determine the prevalence of altered 
immunological tests and their clinical significance in patients with clinically isolated 
syndrome (CIS) suggestive of multiple sclerosis (MS). 
Patients and methods: The information was gathered from medical records of patients 
hospitalized in the Referral Center for Demyelinating Diseases in the 2008-2010 period. All 
patients had ANA, ENA profile, ANCA, aCl IgG and IgM, C3, C4, CH50, anti-TPO, AST 
and RF antibodies tested. 
Results: From 726 patients with CIS that were reviewed, the complete battery of 
immunological tests was performed in 418 of them (57.6%), representing our cohort. Altered 
tests were found in 235 patients (56.2%); 73 (17.4%) had positive antinuclear antibodies, 14 
(3.3%) had positive ENA, 47 (11.2%) had positive aCI- IgG, 83 (19.8%) had positive 
aCIIgM, and 13 (3.1%) had anti TPO antibodies. We found no correlation between ANA, aCl 
IgG or IgM positivity (ANA vs aCL IgG p=0,554; ANA vs aCL IgM p=0,19; aCL IgG vs 
aCL IgM, p=0,155). None of the patients had any clinical manifestations other than MS 
symptoms. 
Conclusion: These results indicate that significant number of patients with CIS have altered 
immunological tests but nevertheless none of them had clinical expression of any other 
autoimmune disease making them clinically insignificant. In conclusion there is no need to 
perform expensive immunological work-up in all patients with CIS. Contrary, our results 
argue for more focused testing rather than a battery of screening tests.   
 
Key words: clinically isolated syndrome, multiple sclerosis, differential diagnosis, 
autoantibodies 
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Introduction 
 
The differential diagnosis of multiple sclerosis (MS) is very broad, however most of these MS 
mimics are rare conditions seldom seen in clinical practice. On the other hand, MS diagnostic 
criteria have emphasized that alternative explanation for the clinical presentation must be 
considered and excluded before a diagnosis of MS can be made. Recently a consensus 
approach on differential diagnosis of MS described an effort to guide the clinical, laboratory, 
and imaging assessment of patients with a possible diagnosis of MS, so as to help satisfy the 
requirement for “no better explanation”. [1] The International Panel did not recommend 
extensive testing. Rather, it recommended that alternative diagnoses should be considered and 
pursued if needed. The special problem in the differential diagnosis of MS represents various 
laboratory tests that are often used as a screening tool for possible MS mimics. It has been 
suggested that screening suspected MS patients with an unvarying battery of tests seldom 
generates a different diagnosis and more often leads to confusing false positive results, this 
being especially true of many tests ordered for the evaluation of systemic, inflammatory, 
autoimmune, “collagen vascular” diseases. [2] 
The aim of this study was to determine the prevalence of altered immunological tests and 
their clinical significance in patients with clinically isolated syndrome (CIS) suggestive of 
MS. 
 
Patients and methods 
 
This was retrospective, observational study. The information was gathered from medical 
records of patients hospitalized in the Referral Center for Demyelinating Diseases in the 
2008-2010 period. Charts of all patients with the diagnosis of CIS were reviewed. All patients 
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with anti-nuclear antibodies (ANA), extractable nuclear antigen (ENA) profile, antineutrophil 
cytoplasmic antibodies (ANCA), anticardiolipin (aCl) IgG and IgM antibodies, C3, C4, 
CH50, anti-thyroid peroxidase antibodies (anti-TPO), anti-streptolysine titer (AST), 
rheumatoid factor (RF) tested were included in the study. All tests were performed in the 
same laboratory using standardized methods suggested by the manufacturer. 
The difference between postitive and negative tests (ANA, aCL IgG and IgM) was analyzed 
by t test for independent samples. P levels of <0.05 were considered as significant. Statistical 
analysis was performed using SPSS 19.0 statistical software. 
 
Results 
 
From 726 patients with CIS that were reviewed, the complete battery of immunological tests 
was performed in 418 of them (57.6%), representing our cohort. Other patients have been 
referred from first and secondary level centers wirh already performed immunological work-
up, so we did not include them in this analysis beacuse of laboratory differences. Altered tests 
were found in 235 patients (56.2%) (Table 1 and Figure 1). Seventy three patients (17.4%) 
had positive antinuclear antibodies (6 patients had homogeneous, 54 speckled, 2 nucleolar and 
1 cytoplasmatic pattern). ENA was positive in 14 patients (3.3%); ENA profile was: SS-A 
four patients, Slc 70 one patient, anti-double stranded DNA (dsDNA) one patient, NuMa one 
patient, DNAtopo-1 four patients, CENP-B one patient, Jo-1 one patient and U1 
ribonucleoprotein (U1-RNP) one patient. Furthermore, 47 patients (11.2%) had positive aCI 
IgG, while aCI IgM was positive in 83 patients (19.8%). aCl IgG titers varied from 10 – 38 
GPL U/ml (36 patients had weakly positive (10-20 GPL U/ml) and 11 patients had 
moderately positive titers (21-40 GPL U/ml)). aCl IgM titers varied from 10 – 140 MPL U/ml 
(65 patients had weakly positive (10-20 MPL U/ml), 8 patients had moderately positive titers 
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21-30 MPL U/ml and 10 patients had highly positive titers > 30 MPL U/ml). We found no 
significance between ANA, aCl IgG or IgM positivity (ANA vs aCL IgG p=0,554; ANA vs 
aCL IgM p=0,19; aCL IgG vs aCL IgM, p=0,155). 
Anti TPO antibodies were found in 13 patients (3.1%) in the range from 28 to > 2000 IJ/ml 
(normal range < 10 IJ/ml). C3 was changed in 63 patients (15.1%) (range 0.58-1.92 g/l, 
normal values 0.90-1.80), and C4 in 16 patients (3.8%) (range 0.41-0.67 g/l, normal value 
0.10-0.40). AST was elevated in 53 patients (12.7%) and 9 (2.1%) had positive RF. None of 
the patients had any clinical manifestations other than MS symptoms. 
 
Discussion 
 
Many autoantibodies have been identified in both, serum and CSF, of MS patient but 
unfortunately, there is no autoantibody described being exclusively expressed in MS patients 
compared to the respective fluids of healthy individuals [3]. Recent proteomic studies on the 
other hand demonstrated that autoantibody in sera or CSF of MS patients are reactive to a 
panel of proteins, rather than a single protein, suggesting a MS-specific pattern of 
autoantibodies [4]. Therefore it is not surprising that many studies have shown present 
different autoantibodies that are used for the evaluation of systemic, inflammatory, 
autoimmune, “collagen vascular” diseases in sera of MS patients. Our study is the first to 
evaluate the presence of these autoantibodies in patients with CIS, and have shown similar 
percentage of positive autoantibodies in CIS patients compared with previous results in 
relapsing remitting or primary progressive MS patients. 
The frequency of antinuclear antibodies ANA in patients with clinically definite MS varies 
from 2.5% to 81% of sera according to the study [5-11]. Most of these studies found no 
correlation between the presence of ANA and symptoms of SLE, although a correlation 
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between ANA and MS disease activity was observed by Collard et al [10]. We have found 
positive ANA titers in 17.4% of CIS patients, and none of our patients had symptoms of SLE. 
Recent studies showed a prevalence of aCl in MS patients of 4.8–44% of cases [11-16]. 
Contrary to our results, some studies have shown higher positivity of aCl IgG than aCl IgM in 
MS patients [16]. In our CIS cohort, 11.2% patients had positive aCI- IgG, and 19.8% 
aCIIgM titers. It is interesting that aCl IgG titers were weakly or moderately positive, while 
21.7% of patients with positive aCl IgM had moderately to high titers. As well, although we 
did not find any correlation between ANA and aCl positivity, other have found opposite 
results [16]. Most of the published studies found no correlation between aCl and age, sex, 
disease duration, clinical classification, clinical evolution, or peculiar clinical symptoms. 
Contrary to previous reports showing high titres of anti-TPO antibodies in 21.7% MS 
patients, we found small percentage of CIS patients with positive titers [17].This may be in 
line with the observation that these antibodies are associated with clinical disease activity. As 
well, MRI analysis showed significantly higher T2 lesion volume in patients with positive aCl 
or anti-TPO antibodies after correction for disease duration [18]. On the other hand some 
studies have shown that there were no significant differences in autoantibodies (ANA, anti-
TPO) frequency or titres between MS and control subjects [19]. Regarding the complement 
levels, C3 was changed in 15.1% and C4 in 3.8% of our cohort. These changes however were 
slightly below normal limits for C3, and slightly above normal limits for C4. Previous studies 
have shown that the mean values of the complement levels of the MS patients did not differ 
from the values in a normal population [20]. 
This study has several limitations. This was observational, retrospective study with a referral 
bias, because all patients came from tertiary center specialized in MS. CIS patients are often 
stratified for risk for MS based on imaging and CSF findings. All patients in this study had 
demyelinating lesions on the brain MRI, however we did not correlate the MRI or CSF results 
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with the results of immunological testing. Other two shortcomings are that the study relied on 
the documentation of clinical symptoms in the patients' charts and that there were no follow-
up data so some patients could have had early or incipient connective tissue disease that 
declared itself subsequently.   
However this is a first study of this kind with CIS patients with a large number of patients 
included. 
 
Conclusion 
 
These results indicate that significant number of patients with CIS have altered 
immunological tests but nevertheless none of them had clinical expression of any other 
autoimmune disease. In conclusion there is no need to perform expensive immunological 
work-up in all patients with CIS. Contrary, our results argue for more focused testing rather 
than a battery of screening tests. 
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Tables 
Table 1. Number and percentage of patients with altered autoantibodies. 
Test performed Number (percentage) of positive tests 
ANA 73 (17.4%) 
ANA pattern 6 homogeneous, 54 speckled, 2 nucleolar and 1 cytoplasmatic 
ENA screen 14 (3.3%) 
ENA profile 4 SS-A, 1 Slc 70, 1 dsDNA, 1 NuMa, 4 DNAtopo-1, 1 CENP-B, 1 Jo-1, 1 
U1-RNP  
aCl IgG 47 (11.2%) 
aCl IgM 83 (19.8%) 
Anti-TPO 13 (3.1%) 
C3 63 (15.1%) 
C4 16 (3.8%) 
AST 53 (12.7%) 
RF 9 (2.1%) 
Anti-nuclear antibodies (ANA), extractable nuclear antigen (ENA), antineutrophil 
cytoplasmic antibodies (ANCA), anticardiolipin (aCl) IgG and IgM antibodies, complement 
(C3, C4), anti-thyroid peroxidase antibodies (anti-TPO), anti-streptolysine titer (AST), 
rheumatoid factor (RF), anti-double stranded DNA (dsDNA), U1 ribonucleoprotein (U1-
RNP) 
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Figures 
 
Figure 1. Number of patients with normal or altered autoantibodies. 
 
 
 
